For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope as more treatment options ...

Beyond NEC, LBL-024 has shown encouraging early activity in other tumor types, including small cell lung cancer (SCLC), ovarian cancer (OC), biliary tract cancer (BTC), and with strong potential ...

New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ ...

(2) Small-cell lung cancer (SCLC), sometimes called oat-cell carcinoma, accounts for about 10 to 15 percent of lung cancers. (2) This cancer is a type of neuroendocrine tumor containing cells that ...

Zai Lab presented updated Phase 1 data for ZL-1310, an investigational DLL3-targeted antibody-drug conjugate (ADC) for ...

NCT05539430 is a Phase 1, open label, dose escalation, multicenter study to evaluate Claudin 18.2-targeting CAR-T cells (LB1908) in adult patients with unresectable, locally advanced or metastatic ...

A new combination therapy that pairs a radiopharmaceutical (177 Lu-DOTATATE) with a DNA-repair blocker (olaparib) has been deemed feasible and tolerable for neuroendocrine cancer patients.

177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) is a mainstay strategy for low- to intermediate-grade metastatic neuroendocrine tumor patients. While this targeted radiopharmaceutical ...

Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In ...